Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Anaptysbio, Inc. (NASDAQ:ANAB) Director Dennis M Fenton sold 3,015 shares of common stock on June 18, 2025, at a price of $23.97, totaling $72,269. Following the transaction, Fenton directly owns 4,965 shares of Anaptysbio. The sale comes amid a strong 60.76% price surge over the past six months, with the stock currently trading above its Fair Value according to InvestingPro analysis.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 22, 2024. The shares were sold to cover tax obligations related to the vesting of restricted stock units on June 15, 2025. The company maintains a strong liquidity position with a current ratio of 8.25, though InvestingPro data reveals 11 additional key insights about the company’s financial health.
In other recent news, AnaptysBio has reported promising results from its Phase 2b trial for the rheumatoid arthritis drug, rosnilimab. The trial, involving 424 patients, showed that rosnilimab achieved low disease activity and remission with a favorable safety profile, and its efficacy was comparable to JAK inhibitors. Analysts from Stifel and TD Cowen have reiterated their Buy ratings, citing the drug’s impressive efficacy and safety. H.C. Wainwright upgraded AnaptysBio from Neutral to Buy, highlighting the significant maintenance of clinical responses even during off-treatment periods. Guggenheim analysts also raised their price target for AnaptysBio shares to $90, maintaining a Buy rating, and emphasized the company’s robust financial status with a cash reserve of $383 million. AnaptysBio’s strategic partnership with GSK is expected to yield significant royalties and milestone payments, with Jemperli sales projected to exceed $2.5 billion. The company is also on track to repay its $600 million obligation to Sagard, which will enhance cash flow post-repayment. Future developments include the awaited ulcerative colitis trial data in the fourth quarter of 2025, which could further influence AnaptysBio’s strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.